Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 1/2 2Phase EARLY_PHASE1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Breast 2

Conditions

Breast Neoplasms 34Ovarian Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Prostatic Neoplasms 2Neoplasms by Site 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Advanced Solid Tumors 2Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Solid Tumor, Adult 1Neoplasm Metastasis 1Melanoma 1HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1HR+/HER2- Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-positive Breast Cancer 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Ductal, Breast 1Brain Neoplasms 1

Interventions

Docetaxel 33Prednisone 28enzalutamide 19Abiraterone Acetate 13pembrolizumab 11gallium 68 PSMA-11 9Leuprolide 9Radiotherapy 8Pluvicto 8Magnetic Resonance Spectroscopy 8Nivolumab 7Estramustine 7abiraterone 6Radiotherapy, Intensity-Modulated 6Goserelin 6Carboplatin 6Biopsy 6olaparib 5cemiplimab 5bicalutamide 5Specimen Handling 5Paclitaxel 5Cyclophosphamide 5temsirolimus 4orteronel 4darolutamide 4cabazitaxel 4acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4Sirolimus 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Prostatic Neoplasms × Fulvestrant × Clear all
NCT07288359 2026-05-27

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Novartis

Phase 1/2 Recruiting
205 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT07570966 2026-05-06

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Novartis

Phase 1/2 Not yet recruiting
217 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡